News

July 2015

C2 Therapeutics receives 510(k)

Redwood City, Calif.July 29, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced US Food and Drug Administration (FDA) 510(k) clearance for the Coldplay Cryoballoon™ Full Ablation System and the Coldplay Cryoballoon™ Swipe Ablation System.

“The clearance of Coldplay Cryoballoon Full and Swipe Systems is an important milestone in broadening the company’s portfolio,” said Peter Garcia-Meza, President and CEO of C2 Therapeutics. “The Full and Swipe Ablation Systems will be critical in allowing physicians to ablate larger areas of tissue in endoscopic applications.”

Click here to see full release.

Successful Safety and Dosing Results Published

Redwood City, Calif.July 20, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced the publication of excellent safety and dosing data related to the company’s Coldplay Cryoballoon™ Focal Ablation System.  Results from the prospective, non-randomized study titled, “Treatment of Barrett’s Esophagus with a novel focal cryoablation device: a safety and feasibility study” were published in the latest edition of the scientific journal Endoscopy.

Click here to see full release.

May 2014

Two Clinical Studies to be Presented at DDW 2014

Redwood City, Calif. – May 2, 2014 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer, today announced that data from two clinical studies evaluating the therapeutic impact of its Coldplay Cryoballoon Focal Ablation System will be presented at Digestive Disease Week® (DDW®), on May 6th in Chicago, IL.

C2 Therapeutics DDW 2014 Clinical Study Announcement Card.

Click here for full press release.

C2 Therapeutics Announces Excellent Interim Safety and Efficacy Results of Cryoballoon Ablation

C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced excellent interim results for its Coldplay Cryoballoon Focal Ablation System at the Digestive Disease Week (DDW) in Chicago. Data from the study titled, “Clinical evaluation of a new CryoBalloon Focal Ablation System for the elimination of Barrett’s esophagus” were presented in a poster session today by Bas Weusten, MD, Professor of Innovative Gastrointestinal Endoscopy Senior Gastroenterologist, St. Antonius Hospital Nieuwegein, The Netherlands, and trial’s Principal Investigator.

Click here for full release.

August 2013

C2 Therapeutics Receives FDA Clearance

C2 Therapeutics’ Receives FDA Clearance for Next Generation Cryoballoon Ablation System

Redwood City, Calif. – August 22, 2013 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus), today announced that it received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Cryoballoon Focal Ablation System.  This is the company’s second 510(k) clearance and will be working to introduce Cryoballoon ablation in the United States.  nitial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation …

Click here to see full release.

June 2013

West Penn Allegheny Clinical Trial Tests New Barrett’s Esophagus Treatment

West Penn Allegheny Health System researchers are investigating whether a new ablation technology can provide safer and more effective treatment for patients with Barrett’s Esophagus, a condition associated with gastroesophageal reflux disease (GERD) that can progress to esophageal cancer if left untreated.

Click here for the full story.

MKTG 1071 REV A